Corcept Therapeutics Incorporated (CORT) News

Corcept Therapeutics Incorporated (CORT): $23.96

-0.36 (-1.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CORT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter CORT News Items

CORT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CORT News Highlights

  • For CORT, its 30 day story count is now at 3.
  • Over the past 13 days, the trend for CORT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DRRX, DRUG and ROAD are the most mentioned tickers in articles about CORT.

Latest CORT News From Around the Web

Below are the latest news stories about CORCEPT THERAPEUTICS INC that investors may wish to consider to help them evaluate CORT as an investment opportunity.

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

In this article we are going to estimate the intrinsic value of Corcept Therapeutics Incorporated ( NASDAQ:CORT ) by...

Yahoo | January 24, 2023

Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

Yahoo | January 17, 2023

Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?

Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | January 11, 2023

7 Undervalued Biotech Stocks to Buy Before They Boom

While medical innovations offer tremendous appeal, investors can still get a discount in this sector via undervalued biotech stocks to buy.

Josh Enomoto on InvestorPlace | December 29, 2022

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

It is hard to get excited after looking at Corcept Therapeutics' (NASDAQ:CORT) recent performance, when its stock has...

Yahoo | December 29, 2022

Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Yahoo | December 20, 2022

Our 7 Top Biotech Stock Picks for 2023

Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.

Josh Enomoto on InvestorPlace | December 9, 2022

Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals

MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has entered into an agreement with Hikma Pharmaceuticals USA Inc. ("Hikma") resolving patent litigation related to Korlym®, Corcept’s medication for the treatment

Yahoo | December 8, 2022

Corcept Therapeutics Provides Miricorilant Clinical Development Update

MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced an update to its programs evaluating the proprietary selective cortisol modulator miricorilant in patients with antipsychotic-induced weight gain (AIWG) and non-alcoholic

Yahoo | December 8, 2022

Jefferies Sticks to Its Buy Rating for Corcept Therapeutics (CORT)

Jefferies analyst Dennis Ding maintained a Buy rating on Corcept Therapeutics (CORT - Research Report) yesterday and set a price target of $35.00. The company's shares closed yesterday at $26.07.According to TipRanks, Ding is an analyst with an average return of -27.1% and a 29.41% success rate. Ding covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, NGM Biopharmaceuticals, and Roivant Sciences.Currently, the analyst consensus on Corcept Therapeutics is a Moderate Buy with an average price target of $32.00, implying a 22.75% upside from current levels. In a report released on November 7, H.C. Wainwright also maintained a Buy rating on the stock with a $33.00 price target.

Christine Brown on TipRanks | November 22, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6074 seconds.